Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis.
Open Access
- 1 March 2011
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 28 (7) , 1622-30
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Therapeutic options for rheumatoid arthritisExpert Opinion on Pharmacotherapy, 2009
- Rheumatoid arthritisThe Lancet, 2009
- Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced ArthritisThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis RatsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- Modeling and Simulation of Abatacept Exposure and Interleukin‐6 Response in Support of Recommended Doses for Rheumatoid Arthritis1The Journal of Clinical Pharmacology, 2007
- Pharmacokinetics of Murine p75-Fc Fusion Protein and MP6-XT22 Anti-Murine TNF-α mAb in MiceJournal of Investigative Dermatology Symposium Proceedings, 2007
- Modulation of T Cell Function by Combination of Epitope Specific and Low Dose Anticytokine Therapy Controls Autoimmune ArthritisPLOS ONE, 2006
- EtanerceptDrugs, 1999
- Comparison of four basic models of indirect pharmacodynamic responsesJournal of Pharmacokinetics and Biopharmaceutics, 1993